E
SCYNEXIS, Inc. SCYX
$0.76 $0.0913.09% NASDAQ
Recommendation
Prev Close
$0.67
Volume
516
Avg Vol (90D)
530,620
Market Cap
$28.05M
Dividend & Yield
--
52-Week Range
$0.57 - $1.31
P/E (TTM)
--
EPS (TTM)
-$0.51
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky
1/23/2026 - Simply Wall St
Scynexis (SCYX) Gains FDA Designations for Antifungal Therapy SCY-247
1/21/2026 - GuruFocus
Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247
1/21/2026 - The Fly
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations ...
1/21/2026 - GuruFocus
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
1/21/2026 - Globe Newswire
FEDERATED HERMES, INC. Acquires Additional Shares in SCYNEXIS Inc.
1/15/2026 - GuruFocus
SCYNEXIS granted Nasdaq extension to regain bid price compliance
12/22/2025 - Seeking Alpha - Healthcare
SCYNEXIS granted Nasdaq extension to regain bid price compliance
12/22/2025 - SeekingAlpha.com: All News
Scynexis granted 180-day extension by Nasdaq to regain compliance
12/22/2025 - TipRanks Financial Blog
Scynexis granted 180-day extension by Nasdaq to regain compliance
12/22/2025 - The Fly
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
12/22/2025 - GuruFocus
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
12/22/2025 - Globe Newswire
SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp's Growth Path
12/19/2025 - TipRanks Financial Blog
Scynexis completes transfer of BREXAFEMME NDA to GSK
11/19/2025 - The Fly
SCYNEXIS Completes Transfer of BREXAFEMME New Drug Application to GSK
11/19/2025 - Globe Newswire
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns ...
11/17/2025 - GuruFocus
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration
11/17/2025 - TipRanks Financial Blog
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration
11/17/2025 - The Fly
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
11/17/2025 - Globe Newswire
Scynexis reports Q3 EPS (17c), consensus (20c)
11/5/2025 - The Fly
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/5/2025 - GuruFocus
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/5/2025 - Globe Newswire
Guggenheim Lowers Price Target for SCYNEXIS (SCYX) but Maintains Buy Rating SCYX Stock News
10/28/2025 - GuruFocus
Guggenheim Keeps Their Buy Rating on SCYNEXIS (SCYX)
10/28/2025 - TipRanks Financial Blog
Scynexis price target lowered by $1 at Guggenheim, here's why
10/28/2025 - The Fly
Income Statement
Total Revenue (TTM)
$2.93M
EBITDA (TTM)
-$7.91M
EBIT (TTM)
-$34.63M
Net Income (TTM)
-$25.30M
Balance Sheet
Total Assets (Q)
$51.07M
Total Debt (Q)
$2.28M
Total Liabilities (Q)
$14.64M
Book Value Per Share (Q)
$0.8683
Cash Flow
Cash from Operations (TTM)
-$33.59M
Cash from Investing (TTM)
$33.51M
Cash from Financing (TTM)
-$14.21M
Net Change in Cash (TTM)
-$14.29M
Filings
Filing Date
Wednesday, November 5, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
0.90
7-Day Total Return
15.30%
30-Day Total Return
16.10%
60-Day Total Return
-1.83%
90-Day Total Return
-32.51%
Year to Date Total Return
18.39%
1-Year Total Return
-28.69%
2-Year Total Return
-58.92%
3-Year Total Return
-55.54%
5-Year Total Return
-90.68%
52-week Low
Nov 17, 2025 - $0.57
52-week High
Sep 12, 2025 - $1.31
Valuation
Market Cap
$28.05M - Nano Cap
Enterprise Value
-$7.59M
Price/Sales (TTM)
11.39
Price/Book (Q)
0.77
Dividends and Shares
Shares Outstanding
49.90M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.scynexis.com
Phone Number
201 884 5485
Address
1 Evertrust Plaza
Jersey City, NJ 07302-6548
Country
United States
Year Founded
1999
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment... more
NASDAQ 01/22/2026 4:00PM Eastern Quotes delayed